SCOPUS 정보 검색 플랫폼

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma

(1) Beatty, Gregory L a

a UNIVERSITY OF PENNSYLVANIA (United States)

Author keywords

Adoptive cell therapy; Cancer; Chimeric antigen receptor; Epitope spreading; Immunosurveillance; Pancreas; T cell

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CHIMERIC PROTEIN; FLUORODEOXYGLUCOSE F 18; MESOTHELIN; UNCLASSIFIED DRUG;

ARTICLE; ASCITES FLUID ANALYSIS; BIOLOGICAL ACTIVITY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CANCER THERAPY; CELL ENGINEERING; CELL INFILTRATION; CELL TRANSFER; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DRUG UPTAKE; FEASIBILITY STUDY; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; PANCREAS ADENOCARCINOMA; PATIENT SAFETY; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME;

EID: 84902578812 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.4161/onci.28327 Document Type: Article

Times cited : (9)

References (10)

1
- 84862903106
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
- PMID:22658128
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
- (2012) N Engl J Med , vol.366 , pp. 2455-2465
- Brahmer, J.R.¹ Tykodi, S.S.² Chow, L.Q.³ Hwu, W.J.⁴ Topalian, S.L.⁵ Hwu, P.⁶ Drake, C.G.⁷ Camacho, L.H.⁸ Kauh, J.⁹ Odunsi, K.¹⁰

2
- 84862859820
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
- PMID:22658127
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
- (2012) N Engl J Med , vol.366 , pp. 2443-2454
- Topalian, S.L.¹ Hodi, F.S.² Brahmer, J.R.³ Gettinger, S.N.⁴ Smith, D.C.⁵ McDermott, D.F.⁶ Powderly, J.D.⁷ Carvajal, R.D.⁸ Sosman, J.A.⁹ Atkins, M.B.¹⁰

3
- 77954801079
- Improved survival with ipilimumab in patients with metastatic melanoma
- PMID:20525992
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
- (2010) N Engl J Med , vol.363 , pp. 711-723
- Hodi, F.S.¹ O'Day, S.J.² McDermott, D.F.³ Weber, R.W.⁴ Sosman, J.A.⁵ Haanen, J.B.⁶ Gonzalez, R.⁷ Robert, C.⁸ Schadendorf, D.⁹ Hassel, J.C.¹⁰

4
- 77958050577
- Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
- PMID:20842054
- Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33:828-33; PMID:20842054; http://dx.doi.org/10.1097/CJI.0b013e3181eec14c
- (2010) J Immunother , vol.33 , pp. 828-833
- Royal, R.E.¹ Levy, C.² Turner, K.³ Mathur, A.⁴ Hughes, M.⁵ Kammula, U.S.⁶ Sherry, R.M.⁷ Topalian, S.L.⁸ Yang, J.C.⁹ Lowy, I.¹⁰

5
- 84883207410
- Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
- PMID:23924790
- Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr., Donehower RC, Jaffee EM, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013; 36:382-9; PMID:23924790; http://dx.doi.org/10.1097/CJI.0b013e31829fb7a2
- (2013) J Immunother , vol.36 , pp. 382-389
- Le, D.T.¹ Lutz, E.² Uram, J.N.³ Sugar, E.A.⁴ Onners, B.⁵ Solt, S.⁶ Zheng, L.⁷ Diaz Jr, L.A.⁸ Donehower, R.C.⁹ Jaffee, E.M.¹⁰

6
- 84880733312
- Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology
- PMID:23890063
- Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002
- (2013) Immunity , vol.39 , pp. 49-60
- Kalos, M.¹ June, C.H.²

7
- 3543060047
- Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
- PMID:15289501
- Thomas AM, Santarsiero LM, Lutz ER, Armstrong TD, Chen YC, Huang LQ, Laheru DA, Goggins M, Hruban RH, Jaffee EM. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200:297-306; PMID:15289501; http://dx.doi.org/10.1084/jem.20031435
- (2004) J Exp Med , vol.200 , pp. 297-306
- Thomas, A.M.¹ Santarsiero, L.M.² Lutz, E.R.³ Armstrong, T.D.⁴ Chen, Y.C.⁵ Huang, L.Q.⁶ Laheru, D.A.⁷ Goggins, M.⁸ Hruban, R.H.⁹ Jaffee, E.M.¹⁰

8
- 78549253550
- Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor
- PMID:20926399
- Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010; 70:9053-61; PMID:20926399; http://dx.doi.org/10.1158/0008-5472.CAN-10-2880
- (2010) Cancer Res , vol.70 , pp. 9053-9061
- Zhao, Y.¹ Moon, E.² Carpenito, C.³ Paulos, C.M.⁴ Liu, X.⁵ Brennan, A.L.⁶ Chew, A.⁷ Carroll, R.G.⁸ Scholler, J.⁹ Levine, B.L.¹⁰

9
- 84996572349
- Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies
- PMID:24579088
- Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, et al. Mesothelin-specific Chimeric Antigen Receptor mRNA-Engineered T cells Induce Anti-Tumor Activity in Solid Malignancies. Cancer Immunol Res 2014; 2:112-20; PMID:24579088; http://dx.doi.org/10.1158/2326-6066.CIR-13-0170
- (2014) Cancer Immunol Res , vol.2 , pp. 112-120
- Beatty, G.L.¹ Haas, A.R.² Maus, M.V.³ Torigian, D.A.⁴ Soulen, M.C.⁵ Plesa, G.⁶ Chew, A.⁷ Zhao, Y.⁸ Levine, B.L.⁹ Albelda, S.M.¹⁰

10
- 84890207337
- T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
- PMID:24432303
- Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res 2013; 1:26-31; PMID:24432303; http://dx.doi.org/10.1158/2326-6066.CIR-13-0006
- (2013) Cancer Immunol Res , vol.1 , pp. 26-31
- Maus, M.V.¹ Haas, A.R.² Beatty, G.L.³ Albelda, S.M.⁴ Levine, B.L.⁵ Liu, X.⁶ Zhao, Y.⁷ Kalos, M.⁸ June, C.H.⁹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.